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The central role of phosphatidylinositol 3‑kinase (PI3K, p110α) signaling in allowing 
cancer cells to bypass normal growth‑limiting controls has led to the development of 
PI3K(p110α) inhibitors. A challenge in targeting PI3K(p110α) relates to the diverse 
actions of the PI3K pathway in numerous cell types. Recent findings in mice deficient 
in PI3K(p110α) activity in the heart, demonstrate the critical role of this pathway in 
protecting the heart against pathological insults. Mice deficient in PI3K(p110α) displayed 
accelerated heart failure in response to dilated or hypertrophic cardiomyopathy. These 
results help explain the association of cardiomyopathy in cancer patients given tyrosine 
kinase inhibitors and raise concerns for the use of PI3K(p110α) inhibitors in cancer 
patients with cardiovascular risk factors. Interestingly, an inhibitor of the mammalian 
target of rapamycin (a downstream effector of PI3K), did not have adverse effects on the 
heart. A more complete understanding of the complex arms and interactions of the PI3K 
pathway will hopefully lead to the development of anti‑cancer agents without cardiac 
complications.
the PhosPhAtidYlinositAl 3‑KinAse signAling PAthwAY
Phosphatidylinositol	3-kinases	(PI3Ks)	are	a	family	of	lipid	kinases	that	phosphorylate	
the	 hydroxyl	 group	 at	 position	 3	 of	 phosphatidylinositol	 (4,5)	 bisphosphate	 (PIP2)	 to	
produce	the	second	messenger	phosphatidylinositol	(3,4,5)	trisphosphate	(PIP3).
1,2	PI3K	
isoforms	 are	 divided	 into	 three	 classes	 (I,	 II,	 III)	 and	 composed	 of	 several	 subunits.1,2	
Class	I	PI3Ks	are	the	best	characterized	and	are	subdivided	into	class	IA	and	IB.	Class	IA	
PI3Ks	consist	of	a	catalytic	subunit	(p110α,	p110b	and	p110d)	and	a	regulatory	subunit	
(p85α,	 p55α,	 p50α,	 p85b,	 and	p55g).	They	 are	 activated	by	 receptor	 tyrosine	 kinases	
e.g.,	 insulin	 and	 insulin-like	growth	 factor	1	 receptors	 (IGF1R;	Fig.	1).	Other	 tyrosine	
kinase	receptors	like	BCR-ABL	and	ErbB2,	which	new	anti-cancer	drugs	target,	also	signal	
through	the	PI3K	pathway.3,4	Class	IB	PI3K	consists	of	the	p110g	catalytic	subunit	and	
the	p101	regulatory	 subunit	and	 is	 activated	by	G-protein-coupled	 receptors	 (GPCRs;	
Fig.	1).	Class	I	PI3Ks	produce	PIP3,	a	lipid	second	messenger	that	controls	a	wide	range	
of	cellular	responses.5	Phosphatase	and	tensin	homolog	(PTEN)	negatively	regulates	PI3K	
signaling	 by	 dephosphorylating	 PIP3	 to	 PIP2.	 Akt	 is	 activated	 downstream	 of	 PIP3	 to	
mediate	physiologic	processes.	Substantial	crosstalk	exists	with	other	signaling	networks	at	
all	levels	of	the	PI3K	pathway.6








found	 in	Cowden	 disease,	 a	 familial	 cancer	 syndrome,	 and	 a	 significant	 percentage	 of	
spontaneous	 cancers,	 leading	 to	 constitutive	 activation	 of	 class	 I	 PI3Ks.8,9	 Activating	
mutations	of	PI3K(p110α)	have	also	been	associated	with	diverse	forms	of	cancer	at	high	
frequency.10,11	 Thus,	 uncontrolled	 activation	 of	 the	 PI3K(p110)	 pathway	 is	 a	 critical	
molecular	 mechanism	 by	 which	 cancer	 cells	 bypass	 normal	 growth-limiting	 controls.	


























not All gRowth is bAd: Pi3K(P110α) MediAtes 
PhYsiologic heARt gRowth And PRovides PRotection 
fRoM PAthologic stRess
Growth	 of	 the	 heart	 is	 broadly	 classified	 as	 either	 pathological	
(“bad”)	or	physiological	 (“good”).16	Cardiac	 growth	 in	 response	 to	
pathologic	stimuli	like	hypertension	is	a	poor	prognostic	sign	because	
of	 its	 association	 with	 the	 development	 of	 heart	 failure.17,18	This	
form	of	 growth	 is	 referred	 to	 as	 pathologic	 hypertrophy.	 Signaling	
cascades	 downstream	 of	 GPCR	 have	 been	 implicated	 in	 inducing	
pathologic	 cardiac	 hypertrophy.	 Cardiac	 specific	 overexpression	 of	
Gαq,19	PKCb20	and	calcineurin21	lead	to	hypertrophy,	heart	failure	
and	 premature	 death	 in	 transgenic	 mice.	 (Fig.	 1).	 An	 exception	
to	 the	 association	 of	 heart	 failure	 with	 hypertrophy	 is	 the	 cardiac	







elevated	 6.5-fold,	 heart	 size	 was	 increased	 by	 approximately	 20%,	
and	 cardiac	 function	 and	 lifespan	were	normal.22	 In	 contrast,	 in	 a	
cardiac-specific	mouse	model	 expressing	 a	 dominant	 negative	 (dn)	





inhibiting Pi3K(P110α) in A setting of heARt diseAse
Cardiac	 function	 was	 not	 compromised	 in	 mice	 deficient	 in	
PI3K(p110α)	 under	 basal	 conditions,	 but	 the	 critical	 role	 of	




dilated	 or	 hypertrophic	 cardiomyopathy.26	DnPI3K(p110α)	 trans-
genic	mice	were	genetically	crossed	to	a	transgenic	mouse	model	of	
dilated	cardiomyopathy	(DCM)27	or	subjected	to	pressure	overload	
for	 1	week	 (a	 surgically	 placed	 constriction	 of	 the	 ascending	 aorta	
increases	 the	 pressure	 work	 of	 the	 heart	 to	 induce	 hypertrophic	
cardiomyopathy).28	 The	 transgenic	 mouse	 model	 of	 DCM	 has	 a	
mean	 lifespan	 of	 approximately	 80	 days	 in	 males.	 In	 a	 setting	 of	




These	 data	 suggest	 that	 PI3K(p110α)	 is	 essential	 for	 maintaining	
cardiac	function	in	response	to	a	pathological	cardiac	insult	and	raises	
concerns	 for	 the	 use	 of	 PI3K(p110α)	 inhibitors	 in	 cancer	 patients	
with	cardiovascular	risk	factors.




opathy,	 caPI3K	 transgenic	mice	 with	 increased	 physiological	 heart	
growth	 were	 significantly	 protected	 in	 these	 models.26	 Transgenic	
expression	 of	 caPI3K	 increased	 the	 lifespan	 of	 mice	 with	 dilated	
cardiomyopathy	by	15–20%.	The	 increase	was	 comparable	 to	 that	




To	 understand	 how	 physiological	 signaling/growth	 inhibits	
pathological	 growth,	 we	 isolated	 myocytes	 from	 non-transgenic,	
caPI3K	transgenic	and	dnPI3K	transgenic	hearts.	caPI3K	myocytes	
showed	 a	 blunted	 response	 to	GPCR	 stimulation	whereas	 dnPI3K	
myocytes	showed	an	exaggerated	response.26	These	data	suggest	that	
PI3K(p110α)	can	inhibit	signaling	molecules	downstream	of	GPCR,	
and	explains	how	 inhibition	of	PI3K(p110α)	 could	 accentuate	 the	
unhealthy	response	to	pathologic	stimuli.
PARAdoxicAl effects of MAMMAliAn tARget    
of RAPAMYcin (mtoR) inhibition in the heARt
Inhibitors	 of	 mTOR,	 a	 downstream	 target	 of	 PI3K/Akt	 and	
effector	of	the	growth	response,	are	also	being	developed	as	anti-cancer	




function	 in	 a	 setting	 of	 left	 ventricular	 hypertension	 and	 cardiac	
dysfunction30	 (Fig.	 2B).	 Furthermore,	 rapamycin	 reduced	 cardiac	




complexity	 of	 targeting	 this	 pathway.	 While	 these	 results	 seem	
Figure 1. Schematic of signaling cascades in the heart. PI3K is activated by 
receptor tyrosine kinases (RTK) and G‑protein‑coupled receptors (GPCRs). In 
the heart, PI3K activated by RTK induces physiological cardiac hypertrophy, 
whereas PI3K activated by GPCRs participates in the depressed cardiac 
function associated with pathological hypertrophy. IFG, insulin‑like growth 
factor 1; Ang II, angiotensin II; ET‑1, endothelin 1; mTOR, mammalian target 




















mTOR.	 Inhibiting	mTOR	has	been	 reported	 to	 result	 in	 feedback	
on	Akt	 (Fig.	 1),	 resulting	 in	 increased	 or	 decreased	Akt	 activation	
depending	 on	 the	 exposure	 time.32,33	 Interestingly,	 Akt	 appears	
to	 be	 differently	 regulated	 in	 the	heart.	Myostatin,	 an	 inhibitor	 of	
cardiac	growth,	 inhibited	GPCR	induced	Akt	phosphorylation	but	
not	 receptor	 tyrosine	 kinase	 induced	 phosphorylation.34	 Finally,	
Akt1	 and	 2,	 the	 predominant	 isoforms	 in	 the	 heart	 may	 mediate	
separate	physiologic	processes	induced	by	PI3K.	Akt1	seems	to	effect	
physiologic	 growth	 and	 the	 anti-hypertrophic	 response	 to	 pressure	
overload,	 whereas	 Akt2	may	 effect	 anti-apoptotic	 pathways	 in	 the	
heart.35,36	Rapamycin	might	affect	a	very	specific	arm	of	 the	PI3K	
signaling	 pathway	 that	 leaves	 intact	 the	 salutory	 effects	 of	 PI3K	
activation	in	the	heart.
the PRoMise of A good life AfteR the cAnceR is cuRed
An	 incredible	 demand	 is	 placed	 upon	 the	 mammalian	 heart	
to	 pump	 an	 entire	 lifetime	 without	 any	 significant	mechanism	 to	
replace	 injured	or	 dead	 cells.	Therefore,	 a	 robust	mechanism	must	
exist	 to	ensure	 survival	of	cardiac	myocytes	when	they	are	 stressed.	
It	 is	 not	 surprising	 then,	 that	 cancer	 cells	 and	 the	 heart	 share	 the	
PI3K	 pathway	 as	 a	 molecular	 survival	 mechanism.	 Considered	 in	
this	context,	the	association	of	heart	failure	in	cancer	patients	given	
tyrosine	kinase	 inhibitors,	 like	 traztuzumab	and	 imatinib	mesylate,	
is	 understandable.	 Trastuzumab-related	 cardiomyopathy	 has	 been	
linked	 with	 downregulation	 of	 ErbB2	 signaling,	 and	 imatinib	
mesylate	 is	 thought	 to	 promote	 apoptosis	 and	 heart	 damage	 by	





patients	 given	 tyrosine	 kinase	 or	 PI3K	 inhibitors.	
These	 stressors	 might	 include	 comorbid	 diseases	
like	 hypertension	 or	 other	 chemotherapeutic	 drugs	
with	cardiotoxic	effects.	In	this	regard,	the	incidence	
of	 cardiomyopathy	 has	 declined	 substantially	 in	
breast	cancer	patients	given	trastuzumab	when	such	
issues	 were	 addressed.39	 Inhibition	 of	 maladaptive	
neurohormonal	 responses	 mediated	 by	 GPCR	 in	
the	stressed	heart	during	induction	of	chemotherapy	
could	also	yield	important	long	term	benefits.40
One	 might	 also	 prevent	 cardiomyopathy	 with	
individualized	 or	 combination	 strategies.	 Clearly,	
PI3K	 signaling	 is	 activated	 via	 multiple	 receptor	
types	in	the	heart.	Why	then	do	some	patients	given	
tyrosine	 kinase	 inhibitors	 develop	 heart	 failure	 but	
others	do	not?	Perhaps	these	patients	have	deficiencies	




one	 might	 be	 able	 to	 supplement	 the	 alternative	
pathway	in	the	heart	without	driving	the	oncogenic	
pathway.	 Alternatively,	 it	 has	 been	 suggested	 that	
concurrent	 inhibition	 of	 PI3K(p110α)	 and	mTOR	
may	 be	 required	 for	 complete	 growth	 inhibition.12	
To	date,	the	effects	of	this	treatment	combination	on	
the	heart	have	not	been	comprehensively	addressed,	





The	 data	 explain	 the	 association	 of	 cardiomyopathy	 in	 patients	
given	 tyrosine	 kinase	 inhibitors	 as	 cancer	 chemotherapy	 and	 raise	
the	concern	that	future	PI3K(p110α)	inhibitors	may	cause	an	even	
higher	 incidence	of	heart	 failure.	Fortunately,	 as	 the	 complex	 arms	
and	 interactions	 of	 the	PI3K	pathway	 are	 better	 understood,	hope	
is	 raised	 that	 the	deleterious	 cardiac	 complications	 can	be	avoided.	
Thus,	patients	may	be	offered	 the	dual	promise	of	 a	 cure	 for	 their	
cancer	and	a	good	life.
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